老年睡眠障碍的药物靶点研究进展

doi:10.3969/j.issn.1003-9198.2026.02.004

摘要/Abstract

摘要： 老年睡眠障碍(SD)因其高患病率及与多种老年综合征的复杂共病关系,已成为重要的健康挑战。然而传统镇静催眠药物在老年SD人群中的应用存在显著局限性。本文从流行病学角度探究老年SD的相关影响因素,同时介绍老年SD在神经递质受体、褪黑素受体、蛋白酶受体、细胞因子方面的药物靶点研究进展。最后,本文提出未来需进一步依托基因检测与人工智能技术破解共病介导的靶点交叉作用难题,加速新型多靶点药物的临床转化,同时深化非药物与药物干预的协同机制,构建更契合老年人生理特征的SD精准防治体系。

关键词: 老年人, 睡眠障碍, 药物靶点

Abstract: Sleep disorders (SD) have emerged as a significant health challenge in the elderly due to their high prevalence and complex comorbidity with various geriatric syndromes. However, the application of traditional sedative-hypnotic drugs in the population presents significant limitations. This paper explores the influencing factors of SD in the elderly from an epidemiological perspective, while also reviews research progress on drug targets for SD related to neurotransmitter receptors, melatonin receptors, protease receptors, and cytokines. Finally, it proposes that future research should further leverage genetic testing and artificial intelligence technologies to address comorbidity-mediated cross-interactions among drug targets, accelerate the clinical translation of novel multi-target drugs, deepen the understanding of synergistic mechanisms between non-pharmacological and pharmacological interventions, and ultimately construct a more precise prevention and treatment system for SD that aligns with the physiological characteristics of the elderly.

Key words: aged, sleep disorders, drug target

中图分类号:

R 74

李佳纯, 阎丽, 刘继业, 孙伟民. 老年睡眠障碍的药物靶点研究进展[J]. 实用老年医学, 2026, 40(2): 121-125.

LI Jiachun, YAN Li, LIU Jiye, SUN Weimin. Research progress on drug targets for sleep disorders in the elderly[J]. Practical Geriatrics, 2026, 40(2): 121-125.

参考文献

[1] HÖGL B, ARNULF I, BERGMANN M, et al. Rapid eye movement sleep behaviour disorder: past, present, and future[J]. J Sleep Res, 2022, 31(4): e13612.
[2] JAQUA E E, HANNA M, LABIB W, et al. Common sleep disorders affecting older adults[J]. Perm J, 2023, 27(1): 122-132.
[3] IRANZO A, COCHEN DE COCK V, FANTINI M L, et al. Sleep and sleep disorders in people with Parkinson’s disease[J]. Lancet Neurol, 2024, 23(9): 925-937.
[4] TATINENY P, SHAFI F, GOHAR A, et al. Sleep in the elderly[J]. Mo Med, 2020, 117(5): 490-495.
[5] FEINSILVER S H. Normal and abnormal sleep in the elderly[J]. Clin Geriatr Med, 2021, 37(3): 377-386.
[6] PAPPAS J A, MINER B. Sleep deficiency in the elderly[J]. Sleep Med Clin, 2024, 19(4): 593-606.
[7] HUNT C A, MUN C J, OWENS M A, et al. Sleep, positive affect, and circulating interleukin-6 in women with temporomandibular joint disorder[J]. Psychosom Med, 2022, 84(3): 383-392.
[8] OKS M, FEINSILVER S H. Sleep in the elderly: a common and growing problem[J]. Clin Geriatr Med, 2021, 37(3): ix-x.
[9] GLEESON M, MCNICHOLAS W T. Bidirectional relationships of comorbidity with obstructive sleep apnoea[J]. Eur Respir Rev, 2022, 31(164):210-256.
[10] HERTENSTEIN E, TRINCA E, WUNDERLIN M, et al. Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis[J]. Sleep Med Rev, 2022, 62: 101597.
[11] KIM J H, ELKHADEM A R, DUFFY J F. Circadian rhythm sleep-wake disorders in older adults[J]. Sleep Med Clin, 2022, 17(2): 241-252.
[12] HUO S, CHENG L, LI S, et al. Effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer’s disease and sleep disorder: a randomized controlled trial[J]. Brain Behav, 2022, 12(2): e2488.
[13] POURMOTABBED A, BOOZARI B, BABAEI A, et al. Sleep and frailty risk: a systematic review and meta-analysis[J]. Sleep Breath, 2020, 24(3): 1187-1197.
[14] ADIT I, SINGH S K, JAISWAL A K, et al. Is there a ubiquitous association between sleep disorder and frailty findings from LASI (2017-18)[J]. BMC Geriatr, 2023, 23(1):429.
[15] HONDA H, ASHIZAWA R, KIRIYAMA K, et al. Chronic pain in the frail elderly mediates sleep disorders and influences falls[J]. Arch Gerontol Geriatr, 2022, 99: 104582.
[16] MINER B, KRYGER M H. Sleep in the aging population[J]. Sleep Med Clin, 2020, 15(2): 311-318.
[17] GETANEH F W, SUSSMAN R D, IGLESIA C B. Nocturia: evaluation and management[J]. Am Fam Physician, 2025, 111(6): 515-523B.
[18] WILSON M A, SUMERA A, TAYLOR L W, et al. Phylogenetic divergence of GABA(B) receptor signaling in neocortical networks over adult life[J]. Nat Commun, 2025, 16(1): 4194.
[19] CHEN Y R, SCHULZ P J. The effect of information communication technology interventions on reducing social isolation in the elderly: a systematic review[J]. J Med Internet Res, 2016, 18(1): e18.
[20] CONDON A F, ASAD N, DORE T M, et al. Co-activation of GPCRs facilitate GIRK-dependent current[J]. J Physiol, 2022, 600(22): 4881-4895.
[21] TOOR B, RAY B L, POZZOBON A, et al. Sleep, orexin and cognition[J]. Front Neurol Neurosci, 2021, 45:38-51.
[22] DAUVILLIERS Y, PLAZZI G, MIGNOT E, et al. Oveporexton, an oral orexin receptor 2-selective agonist, in narcolepsy type 1[J]. N Engl J Med, 2025, 392(19): 1905-1916.
[23] KIM S, JO K, HONG K B, et al. GABA and l-theanine mixture decreases sleep latency and improves NREM sleep[J]. Pharm Biol, 2019, 57(1): 65-73.
[24] JOHNSON K A, MARTIN N, NAPPI R E, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT[J]. J Clin Endocrinol Metab, 2023, 108(8): 1981-1997.
[25] YU Q, GUO Q, JIN S, et al. Melatonin suppresses sympathetic vasomotor tone through enhancing GABA(A) receptor activity in the hypothalamus[J]. Front Physiol, 2023, 14: 1166246.
[26] OKAMOTO H H, CECON E, NUREKI O, et al. Melatonin receptor structure and signaling[J]. J Pineal Res, 2024, 76(3): e12952.
[27] SAVINO R, POLITO A N, MARSALA G, et al. Agomelatine: a potential multitarget compound for neurodevelopmental disorders[J]. Brain Sci, 2023, 13(5): 734.
[28] KLOSEN P, LAPMANEE S, SCHUSTER C, et al. MT1 and MT2 melatonin receptors are expressed in nonoverlapping neuronal populations[J]. J Pineal Res, 2019, 67(1): e12575.
[29] PÉREZ-MORALES M, LÓPEZ-COLOMÉ A M, MÉNDEZ-DÍAZ M, et al. Inhibition of diacylglycerol lipase (DAGL) in the lateral hypothalamus of rats prevents the increase in REMS and food ingestion induced by PAR1 stimulation[J]. Neurosci Lett, 2014, 578: 117-121.
[30] LOSGOTT T, KUDLACEK O, YANG J W, et al. The paracetamol metabolite N-acetyl-4-benzoquinoneimine (NAPQI) prevents modulation of K_V7 channels via G-protein coupled receptors by interference with PIP₂ and Ca²⁺ sensitivity[J]. Br J Pharmacol, 2025, 182(6): 1341-1357.
[31] KUME M, AHMAD A, SHIERS S, et al. C781, a β-arrestin biased antagonist at protease-activated receptor-2 (PAR2), displays in vivo efficacy against protease-induced pain in mice[J]. J Pain, 2023, 24(4): 605-616.
[32] NASH J, MEAH M N, WHITTINGTON B, et al. PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies[J]. Arterioscler Thromb Vasc Biol, 2024, 44(4): 987-996.
[33] YANG D F, HUANG W C, WU C W, et al. Acute sleep deprivation exacerbates systemic inflammation and psychiatry disorders through gut microbiota dysbiosis and disruption of circadian rhythms[J]. Microbiol Res, 2023, 268: 127292.
[34] LIU H, YANG C, WANG X, et al. Propofol improves sleep deprivation-induced sleep structural and cognitive deficits via upregulating the BMAL1 expression and suppressing microglial M1 polarization[J]. CNS Neurosci Ther, 2024, 30(7): e14798.
[35] MOHAMMADI I, ADIBPARSA M, YASHOOA R K, et al. Effect of continuous positive airway pressure therapy on blood levels of IL-6, IL-10, IL-18, IL-1β, IL-4, and IL-17 in obstructive sleep apnoea adults: a systematic review, meta-analysis and trial sequential analysis[J]. Int Orthod, 2024, 22(4): 100917.